CN107095657A - 一种新陈代谢类型检测方法以及新陈代谢修复营养配方 - Google Patents
一种新陈代谢类型检测方法以及新陈代谢修复营养配方 Download PDFInfo
- Publication number
- CN107095657A CN107095657A CN201710117940.2A CN201710117940A CN107095657A CN 107095657 A CN107095657 A CN 107095657A CN 201710117940 A CN201710117940 A CN 201710117940A CN 107095657 A CN107095657 A CN 107095657A
- Authority
- CN
- China
- Prior art keywords
- metabolism
- vitamin
- stage
- repaired
- oxidized form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004060 metabolic process Effects 0.000 title claims abstract description 76
- 238000001514 detection method Methods 0.000 title claims abstract description 19
- 235000016709 nutrition Nutrition 0.000 title abstract description 7
- 230000035764 nutrition Effects 0.000 title abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims abstract description 53
- 230000002503 metabolic effect Effects 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 238000009472 formulation Methods 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims abstract description 9
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 9
- 235000001465 calcium Nutrition 0.000 claims abstract description 9
- 239000011777 magnesium Substances 0.000 claims abstract description 9
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 9
- 235000001055 magnesium Nutrition 0.000 claims abstract description 9
- 239000011591 potassium Substances 0.000 claims abstract description 9
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 9
- 235000007686 potassium Nutrition 0.000 claims abstract description 9
- 230000008439 repair process Effects 0.000 claims abstract description 9
- 239000011734 sodium Substances 0.000 claims abstract description 9
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 9
- 235000015424 sodium Nutrition 0.000 claims abstract description 9
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 229940045997 vitamin a Drugs 0.000 claims abstract description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 8
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 8
- 229960000304 folic acid Drugs 0.000 claims abstract description 8
- 235000019152 folic acid Nutrition 0.000 claims abstract description 8
- 239000011724 folic acid Substances 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- 229940091250 magnesium supplement Drugs 0.000 claims abstract description 4
- 230000036772 blood pressure Effects 0.000 claims description 25
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 23
- 235000019710 soybean protein Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000035487 diastolic blood pressure Effects 0.000 claims description 5
- 230000035622 drinking Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 102000004407 Lactalbumin Human genes 0.000 claims description 4
- 108090000942 Lactalbumin Proteins 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 229940083542 sodium Drugs 0.000 abstract description 3
- 238000005067 remediation Methods 0.000 abstract 3
- 108010046377 Whey Proteins Proteins 0.000 abstract 1
- 102000007544 Whey Proteins Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 229940001941 soy protein Drugs 0.000 abstract 1
- 235000021119 whey protein Nutrition 0.000 abstract 1
- 235000011844 whole wheat flour Nutrition 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940019142 folic acid 5 mg Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940033282 vitamin b6 2 mg Drugs 0.000 description 1
- 229940089133 vitamin b6 5 mg Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4866—Evaluating metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于非药物养生领域,具体是一种新陈代谢类型检测方法以及新陈代谢修复营养配方,新陈代谢类型检测方法包括三个检测阶段;新陈代谢修复营养配方,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;快氧化型新陈代谢修复营养组合:包括乳清蛋白、大豆蛋白、维生素A、维生素B12、维生素E、钙和钾;慢氧化型新陈代谢修复营养组合:包括全麦粉、维生素C、叶酸、维生素B6、维生素D、镁和钠。本发明的新陈代谢类型检测方法免抽血、准确度高、无风险且省时,本发明的新陈代谢修复营养配方从非药物角度精准修复人体紊乱的“克氏循环”、激活新陈代谢系统并增强免疫力。
Description
技术领域
本发明属于非药物养生领域,具体是一种新陈代谢类型检测方法以及新陈代谢修复营养配方。
背景技术
生活习惯、饮食习惯和碳水化合物、蛋白质的比例,与整体健康之间存在重要关系。大量证据显示生活方式和行为、饮食习惯、维生素、矿物质对包括糖尿病、心脑血管疾病和癌症的预防和康复具有显著影响。
生命是靠新陈代谢维持的,新陈代谢终止,生命就结束。新陈代谢负责从食物获得营养,在细胞的线粒体把葡萄糖“氧化”变成能量。这个氧化过程称为“克氏循环”。“克氏循环”把葡萄糖变成ATP(三磷酸腺苷)并排出二氧化碳。“克氏循环”减慢或变快,立刻影响营养的吸收或有害物质排出体外,直接影响身体健康。根据“克氏循环”的快慢(葡萄糖氧化变成ATP的速度)把新陈代谢分为两个类型:“快氧化型”和“慢氧化型”,“快氧化型”是“克氏循环”把葡萄糖变成ATP的速度比较快,“慢氧化型”是“克氏循环”把葡萄糖变成ATP的速度比较慢。若属于这两种新陈代谢类型的人群不进行代谢调整,人体就不能产生足够的三磷酸腺苷,人就容易疲劳,严重者会引发糖尿病、恶性肿瘤或神经退行性疾病。
目前,针对未患病人群的新陈代谢类型检测并无相应准确的检测方法,亦没有从非药物角度来修复人体新陈代谢以预防疾病的方案。
发明内容
本发明所要解决的技术问题是提供一种免抽血、准确度高、无风险且省时的针对未患病人群的新陈代谢类型检测方法以及一种从非药物角度精准修复人体紊乱的“克氏循环”、激活新陈代谢系统并增强免疫力的新陈代谢修复营养配方。本发明解决上述技术问题的技术方案如下:一种新陈代谢类型检测方法,包括以下三个阶段:
第一阶段:测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录以作为比较基础;
第二阶段:被测试者饮用浓度大于或等于80%的葡萄糖水,等候15-30min后,再次测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录;
第三阶段:比对第一阶段和第二阶段记录的数据,第二阶段相比第一阶段的血压上升、心率上升、每分钟呼吸次数增多及闭气时间延长,则被测试者为慢氧化型新陈代谢,而第二阶段相比第一阶段的血压下降、心率下降、每分钟呼吸次数减少及闭气时间缩短,则被测试者为快氧化型新陈代谢。
优选地,第一阶段和第二阶段所测试的血压均为舒张压。
优选地,被测试者在测试开始前1小时内不能进食。
注:氧是身体所需的重要元素,肺部负责吸入氧气,呼出二氧化碳。但身体对二氧化碳的需要与氧同样重要,人体组织需要的二氧化碳是氧的3倍,二氧化碳还可以崔进血红蛋白释放氧。氧在细胞线粒体层面,是“克氏循环”氧化葡萄糖的唯一元素,二氧化碳是“克氏循环”的产物之一。若细胞线粒体缺少氧,肺部会不自主的增加呼吸次数,吸入更多的氧,而体内二氧化碳充足,肺部会不自主的减慢呼吸次数,减少氧的吸入。故每分钟呼吸次数是区分“克氏循环”快慢的重要指标之一,闭气时间亦是区分“克氏循环”快慢的重要指标之一。
本发明还公开了一种新陈代谢修复营养配方,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;
快氧化型新陈代谢修复营养组合:包括乳清蛋白、大豆蛋白、维生素A、维生素B12、维生素E、钙和钾;
慢氧化型新陈代谢修复营养组合:包括全麦粉、维生素C、叶酸、维生素B6、维生素D、镁和钠。
优选地,所述快氧化型新陈代谢修复营养组合包括以下按重量份数的组分:取乳清蛋白500~1000份、大豆蛋白500~1000份、维生素A 1~1.5份、维生素B12 0.006~0.01份、维生素E 20~30份、钙80~120份和钾100~200份。
优选地,所述慢氧化型新陈代谢修复营养组合,包括以下按重量份数的组分:取全麦粉2000~3000份、维生素C 200~250份、叶酸3~5份、维生素B6 2~5份、维生素D 0.002~0.005份、镁20~30份和钠0~2份。
注:全麦粉、维生素C、叶酸、维生素B6、维生素D、镁和钠,进入人体后,会令“克氏循环”加快;
乳清蛋白、大豆蛋白、维生素A、维生素B12、维生素E、钙和钾,进入人体后,会令“克氏循环”减慢。
上述新陈代谢修复营养配方的制备方法,快氧化型新陈代谢修复营养组合由其各组份复合制得;慢氧化型新陈代谢修复营养组合由其各组份复合制得
本发明的有益效果是:
本发明的检测方法免抽血、准确度高、无风险且省时,普通人在家中都可以测试,测试方便。
本发明的营养配方从非药物角度精准修复人体紊乱的“克氏循环”、激活新陈代谢系统并增强免疫力,安全高效,为预防因“克氏循环”紊乱导致的疾病具有重要意义,其制备方法简单易行。
具体实施方式
下面将对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案,因此只作为示例,而不能以此来限制本发明的保护范围。
实施例1
一种新陈代谢类型检测方法,包括以下三个阶段:
第一阶段:测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录以作为比较基础;
第二阶段:被测试者饮用浓度为90%的葡萄糖水,等候15min后,再次测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录;
第三阶段:比对第一阶段和第二阶段记录的数据,第二阶段相比第一阶段的血压上升、心率上升、每分钟呼吸次数增多及闭气时间延长,则被测试者为慢氧化型新陈代谢,而第二阶段相比第一阶段的血压下降、心率下降、每分钟呼吸次数减少及闭气时间缩短,则被测试者为快氧化型新陈代谢。
其中,为保证测试准确性,第一阶段和第二阶段所测试的血压均为舒张压,被测试者在测试开始前1小时内不能进食。
一种新陈代谢修复营养配方,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;
快氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:,取乳清蛋白500mg、大豆蛋白500mg、维生素A 1000μg、维生素B12 6μg、维生素E 20mg、钙80mg和钾100mg;
慢氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:取全麦粉2000mg、维生素C 200mg、叶酸3mg、维生素B6 2mg、维生素D 2μg、镁20mg和钠1mg。
上述新陈代谢修复营养配方的制备方法,快氧化型新陈代谢修复营养组合由其各组份混合制得;慢氧化型新陈代谢修复营养组合由其各组份混合制得,各类型的人群根据自身新陈代谢类型内服即可。
实施例2
一种新陈代谢类型检测方法,包括以下三个阶段:
第一阶段:测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录以作为比较基础;
第二阶段:被测试者饮用浓度为85%的葡萄糖水,等候20min后,再次测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录;
第三阶段:比对第一阶段和第二阶段记录的数据,第二阶段相比第一阶段的血压上升、心率上升、每分钟呼吸次数增多及闭气时间延长,则被测试者为慢氧化型新陈代谢,而第二阶段相比第一阶段的血压下降、心率下降、每分钟呼吸次数减少及闭气时间缩短,则被测试者为快氧化型新陈代谢。
其中,为保证测试准确性,第一阶段和第二阶段所测试的血压均为舒张压,被测试者在测试开始前1小时内不能进食。
一种新陈代谢修复营养配方,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;
快氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:取乳清蛋白800mg、大豆蛋白800mg、维生素A 1200μg、维生素B12 8μg、维生素E 25mg、钙100mg和钾150mg;
慢氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:取全麦粉2500mg、维生素C 220mg、叶酸4mg、维生素B6 4mg、维生素D 4μg、镁25mg和钠1mg。
上述新陈代谢修复营养配方的制备方法,快氧化型新陈代谢修复营养组合由其各组份混合制得;慢氧化型新陈代谢修复营养组合由其各组份混合制得,各类型的人群根据自身新陈代谢类型内服即可。
实施例3
一种新陈代谢类型检测方法,包括以下三个阶段:
第一阶段:测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录以作为比较基础;
第二阶段:被测试者饮用浓度为80%的葡萄糖水,等候15min后,再次测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录;
第三阶段:比对第一阶段和第二阶段记录的数据,第二阶段相比第一阶段的血压上升、心率上升、每分钟呼吸次数增多及闭气时间延长,则被测试者为慢氧化型新陈代谢,而第二阶段相比第一阶段的血压下降、心率下降、每分钟呼吸次数减少及闭气时间缩短,则被测试者为快氧化型新陈代谢。
其中,为保证测试准确性,第一阶段和第二阶段所测试的血压均为舒张压,被测试者在测试开始前1小时内不能进食。
一种新陈代谢修复营养配方,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;
快氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:取乳清蛋白1000mg、大豆蛋白1000mg、维生素A 1500μg、维生素B12 10μg、维生素E 30mg、钙120mg和钾200mg;
慢氧化型新陈代谢修复营养组合,包括以下按人体每日所需重量计的组分:取全麦粉3000mg、维生素C 250mg、叶酸5mg、维生素B6 5mg、维生素D 5μg、镁30mg和钠2mg。
上述新陈代谢修复营养配方的制备方法,快氧化型新陈代谢修复营养组合由其各组份混合制得;慢氧化型新陈代谢修复营养组合由其各组份混合制得,各类型的人群根据自身新陈代谢类型内服即可。
实施例1~3的有益效果是:
检测方法免抽血、准确度高、无风险且省时,普通人在家中都可以测试,测试方便。
营养配方从非药物角度精准修复人体紊乱的“克氏循环”、激活新陈代谢系统并增强免疫力,安全高效,为预防因“克氏循环”紊乱导致的疾病具有重要意义,其制备方法简单易行。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围,其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (7)
1.一种新陈代谢类型检测方法,其特征在于,包括以下三个阶段:
第一阶段:测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录以作为比较基础;
第二阶段:被测试者饮用浓度大于或等于80%的葡萄糖水,等候15-30min后,再次测试被测试者的血压、心率、每分钟呼吸次数和闭气时间,并记录;
第三阶段:比对第一阶段和第二阶段记录的数据,第二阶段相比第一阶段的血压上升、心率上升、每分钟呼吸次数增多及闭气时间延长,则被测试者为慢氧化型新陈代谢,而第二阶段相比第一阶段的血压下降、心率下降、每分钟呼吸次数减少及闭气时间缩短,则被测试者为快氧化型新陈代谢。
2.根据权利要求1所述的一种新陈代谢类型检测方法,其特征在于,第一阶段和第二阶段所测试的血压均为舒张压。
3.根据权利要求1或2所述的一种新陈代谢类型检测方法,其特征在于,被测试者在测试开始前1小时内不能进食。
4.一种新陈代谢修复营养配方,其特征在于,包括快氧化型新陈代谢修复营养组合和慢氧化型新陈代谢修复营养组合;
快氧化型新陈代谢修复营养组合:包括乳清蛋白、大豆蛋白、维生素A、维生素B12、维生素E、钙和钾;
慢氧化型新陈代谢修复营养组合:包括全麦粉、维生素C、叶酸、维生素B6、维生素D、镁和钠。
5.根据权利要求4所述的一种新陈代谢修复营养配方,其特征在于,所述快氧化型新陈代谢修复营养组合包括以下按重量份数的组分:乳清蛋白500~1000份、大豆蛋白500~1000份、维生素A 1~1.5份、维生素B12 0.006~0.01份、维生素E 20~30份、钙80~120份和钾100~200份。
6.根据权利要求4所述的一种新陈代谢修复营养配方,其特征在于,所述慢氧化型新陈代谢修复营养组合中,包括以下按重量份数的组分:取全麦粉2000~3000份、维生素C 200~250份、叶酸3~5份、维生素B6 2~5份、维生素D 0.002~0.005份、镁20~30份和钠0~2份。
7.一种如权利要求4-6任一项所述的新陈代谢修复营养配方的制备方法,其特征在于,快氧化型新陈代谢修复营养组合由其各组份混合制得;慢氧化型新陈代谢修复营养组合由其各组份混合制得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710117940.2A CN107095657A (zh) | 2017-03-01 | 2017-03-01 | 一种新陈代谢类型检测方法以及新陈代谢修复营养配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710117940.2A CN107095657A (zh) | 2017-03-01 | 2017-03-01 | 一种新陈代谢类型检测方法以及新陈代谢修复营养配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107095657A true CN107095657A (zh) | 2017-08-29 |
Family
ID=59675533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710117940.2A Pending CN107095657A (zh) | 2017-03-01 | 2017-03-01 | 一种新陈代谢类型检测方法以及新陈代谢修复营养配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107095657A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618395A (zh) * | 2003-11-17 | 2005-05-25 | 杨章民 | 一种用于生理机能监测与信息处理的方法及其装置 |
US20060235282A1 (en) * | 2005-03-17 | 2006-10-19 | Helen Wesolowski | Methods for the treatment of mammals with abnormal glucose tolerance |
CN105725967A (zh) * | 2016-01-30 | 2016-07-06 | 曾晓飞 | 人体新陈代谢分类测定方法 |
US20160324478A1 (en) * | 2015-05-08 | 2016-11-10 | Steven Wayne Goldstein | Biometric, physiological or environmental monitoring using a closed chamber |
CN106137128A (zh) * | 2016-06-24 | 2016-11-23 | 何颖 | 人体健康检测方法 |
US20160358509A1 (en) * | 2009-03-05 | 2016-12-08 | Fat Statz LLC, dba BodySpex | Metrics assessment system for health, fitness and lifestyle behavioral management |
CN106446530A (zh) * | 2016-09-05 | 2017-02-22 | 中山大学 | 一种基于人体运动热生理的仿真风险评估方法及其系统 |
-
2017
- 2017-03-01 CN CN201710117940.2A patent/CN107095657A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618395A (zh) * | 2003-11-17 | 2005-05-25 | 杨章民 | 一种用于生理机能监测与信息处理的方法及其装置 |
US20060235282A1 (en) * | 2005-03-17 | 2006-10-19 | Helen Wesolowski | Methods for the treatment of mammals with abnormal glucose tolerance |
US20160358509A1 (en) * | 2009-03-05 | 2016-12-08 | Fat Statz LLC, dba BodySpex | Metrics assessment system for health, fitness and lifestyle behavioral management |
US20160324478A1 (en) * | 2015-05-08 | 2016-11-10 | Steven Wayne Goldstein | Biometric, physiological or environmental monitoring using a closed chamber |
CN105725967A (zh) * | 2016-01-30 | 2016-07-06 | 曾晓飞 | 人体新陈代谢分类测定方法 |
CN106137128A (zh) * | 2016-06-24 | 2016-11-23 | 何颖 | 人体健康检测方法 |
CN106446530A (zh) * | 2016-09-05 | 2017-02-22 | 中山大学 | 一种基于人体运动热生理的仿真风险评估方法及其系统 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kraaijenga et al. | Evaluation of long term (10-years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer | |
Hodgson et al. | A positive response to a recruitment maneuver with PEEP titration in patients with ARDS, regardless of transient oxygen desaturation during the maneuver | |
CN103238840A (zh) | 银杏叶提取物鱼油软胶囊及其制备方法 | |
Ganio et al. | Effect of various carbohydrate-electrolyte fluids on cycling performance and maximal voluntary contraction | |
Bajerska et al. | Effects of rye bread enriched with green tea extract on weight maintenance and the characteristics of metabolic syndrome following weight loss: a pilot study | |
CN108175089A (zh) | 一种适用于糖尿病患者的全营养配方液 | |
Reay et al. | The glycaemic effects of single doses of Panax ginseng in young healthy volunteers | |
Moga et al. | Bi-level Positive Airway Pressure (BiPAP) with standard exhalation valve does not improve maximum exercise capacity in patients with COPD | |
CN107095657A (zh) | 一种新陈代谢类型检测方法以及新陈代谢修复营养配方 | |
Malenfant et al. | Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension | |
CN108142951A (zh) | 改善术后胰岛素抵抗的营养食品及其制备方法和应用 | |
Kluesner et al. | Scurvy: malnourishment in the land of plenty | |
CN105725967A (zh) | 人体新陈代谢分类测定方法 | |
Barton et al. | Pica for uncooked basmati rice in two women with iron deficiency and a review of ryzophagia | |
Sheehan et al. | Effects of XS® energy drink on aerobic exercise capacity of athletes | |
Alhalabi et al. | Chronic Recurrent Multifocal Osteomyelitis Mimicking Scurvy in a Child: A Case Report | |
RU2201179C2 (ru) | Способ лечения диабетических ретинопатий | |
Nakamura et al. | Thiamine Deficiency in a Nondrinker and Secondary Pulmonary Edema after Thiamine Replenishment | |
Baggott et al. | Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate | |
CN113209168B (zh) | 祛风活血中药组合物及其在治疗或预防紫杉类药物致周围神经病变中的应用 | |
Ordman | Nutritional Steps to Maintain Health and Reduce Cancer Risk | |
Meitei et al. | Analyze The Effect Of Selected Ayurvedic-Herbal Medicines On Cardio-Respiratory Endurance Performance Of Athletes Using Biochemical Variables | |
Rai et al. | A comparative study on the assessment of clinical features of Pandu roga and its subtypes vis a vis various types of anemia | |
Pizzorno et al. | What is natural medicine | |
Zhou et al. | Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: A randomized controlled trial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170829 |
|
RJ01 | Rejection of invention patent application after publication |